

MAY 2025



PROBUS CLUB OF CENTRAL EDMONTON

NEWSLETTER

www.probus-central-edmonton.com

HAPPY FATHERS' DAY



MEETING LOCATION

**Victoria Golf Club
12130 River Valley Rd
NW Edmonton**

Nota Bene: All newsletter photos are sourced from the public domain or with permission

2024-25 EXECUTIVE

President

Scott Watson

Past President

Paul Greenwood

Vice President

Sheila Garner

Treasurer

Jim Drinkwater

Secretary

Dave Raynor

Directors:

Membership

Wayne McKendrick

Communications

Kate Hobin

Programs

Bruce Clark &
Paul Greenwood


Technologies/ Webmaster

Yves Forté

EVENT & TOUR HIGHLIGHTS

May 27 – Tour of Heidelberg Materials, Cement Plant
12640 Inland Way NW, Edmonton

www.heidelbergmaterials.us/



A special tour of Heidelberg Materials, Cement introduced the participants to Heidelberg Materials North America, a leading supplier of cement, aggregates, ready mixed concrete and asphalt. The Edmonton location is focusing on unlocking the future of carbon capture, utilization and storage (CCUS). This is a global first mover initiative designed to revolutionize the cement industry, The facility will play a pivotal role in combating climate change and capturing over 1 million tonnes of CO₂ annually and set a new standard showcasing how sustainability can be integrated in cement production. This new initiative is also designed to be a catalyst for economic growth and job creation with the overall commitment to transition to a low-carbon future and reach net zero greenhouse gas emissions by 2050.

GUEST SPEAKER HIGHLIGHTS

Guest Speaker, April 20: Dr. Jack Jhamandas, Distinguish University Professor of Neurology, UofA Faculty of Medicine. **Topic:** *An Update on Current Alzheimer's Research*


Dr. Jhamandas (BSc Applied Physics & MSc Biophysics - UofA, MD - UofC, PhD Neuroscience - McGill) is a neurologist and neuroscientist whose research specialty is Alzheimer's disease which is funded by the Canadian institute of Health Research and other agencies. He completed his clinical training in Internal Medicine at the Toronto Western Hospital and in Neurology at the Montreal Neurological Institute. He has received many honours: Gold Medal in Medicine from the Royal College of Physicians and Surgeons of Canada, a Killam Professorship and a Tier 1 Canada Research Chair in Alzheimer's Research and was elected as a Fellow of the Canadian Academy of Health Sciences. His published peer reviewed manuscripts are over 100 and he holds several patents. He is President and CEO of Egeiro Pharmaceuticals Inc. co-founded with , Dr. Lorne Tyrrell and Sir Michael Houghton. Dr. Jhamandas' shared his research and knowledge in the development of disease modifying therapies for Alzheimer's disease.



Alzheimer's disease (AD) is the leading cause of dementia, which is associated with memory loss and other cognitive impairments. AD is a progressive disease, which means that symptoms worsen over time until it becomes fatal. There are 50 million people in the world living with dementia, of which AD is the major cause, and this number is expected to double every 20 years. AD has no known cure, although some medications are available to treat the symptoms, extend and improve quality of life. Today, there is a worldwide effort to close this gap and find an effective treatment. Although much effort has been put into developing drugs for this severe disease, all the advanced candidates have either failed in clinical trials or if they work, the benefits are modest and there are troublesome side effects.

Dr. Jack Jhamandas, in collaboration with Dr. Loren Tyrrell and Sir Michael Houghton of the Li Ka Shing Applied Virology Institute, has designed a novel strategy and developed drugs that target a different protein, the amylin receptor. Dr. Jhamandas has shown that the toxic effect of b-amyloid, an abnormal protein found in the brains of AD patients, can be prevented by using drugs that block the amylin receptor. Administration of these drugs to mice that develop AD results in improved cognition





and memory and gets rid of amyloid plaques and inflammation in the brain. This is a unique drug target not constrained by the current approaches that focus on preventing generation of the amyloid or its clearance. Given his timely and ground-breaking research and its strong translational dimension for drug discovery, further development in this area could yield transformative therapy for Alzheimer's disease.

A more detailed account of Dr. Jhamandas and his team's research efforts is profiled in the latest issue of the Edify Magazine (May/June issue).

<https://edifyedmonton.com/urban/innovation-technology/distant-memory/>